RyosukeTsugitomi· @Rtsugitom · X·· 1 天前评分70
正文 · 原文
Although challenges remain in how best to identify MET alterations, this looks like a highly promising treatment option following progression on osimertinib!
#ESMO26
27 浏览 · 0 赞 · 0 转发 · 2 回复
②SAFFRON: Osimertinib + savolitinib vs. platinum-based chemotherapy in patients with EGFR-mutated, MET-overexpressed or MET-amplified NSCLC following progression on osimertinib在 X 查看被引用的帖子
帖内回复
- RyosukeTsugitomi@Rtsugitom
https://x.com/NEJM/status/2114380721066295632?s=20
- RyosukeTsugitomi@Rtsugitom
Are we heading back to the days when we were desperately chasing T790M through repeat biopsies..? But perhaps that's how it should be.
来源：RyosukeTsugitomi · x.com